ArticleAmerican journal of epidemiology2026
Use of the test-negative design to estimate the protective effect of a scalar immune measure: a simulation analysis.
Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Influenza vaccine protection and contact patterns among outpatients with influenza-like illness during the 2024-2025 season in China: a test-negative case-control study.Journal of global health · 2026Article
- Statistical methods for estimating the protective effects of immune markers using test-negative designs.American journal of epidemiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Exposure-proximal antibody levels, or scalar correlates of protection (COPs), are increasingly used to assess infection risk following vaccination or prior infection. A version of the test-negative design (TND), adapted from vaccine effectiveness studies, has been proposed to estimate this relationship, but its validity for continuous immune measures under realistic epidemic conditions remains unclear. We used individual-based transmission models incorporating waning and boosting immunity and simulated two scenarios: one with homogenous baseline risk and another with a high-risk group. Infection risk was modeled as a function of COP, both linearly and nonlinearly. Test-negative design samples were drawn from single or multiple days and analyzed using logistic regression and generalized additive models (GAMs). Model validity, defined as the ability to recover the true COP-infection incidence rate ratio relationship, was evaluated using mean absolute error. Transformed logistic regression recovered the true relationship when the correct functional form was known, including in the presence of confounding. When the parametric model was misspecified, GAMs outperformed logistic regression, particularly with large sample sizes and broad COP coverage. Because the true functional form is often unknown, flexible semiparametric approaches may be preferred in well-powered TND studies with antibody measurements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.